Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Learn About Coagulation Disorders
-What are Bleeding Disorders?
 History of Bleeding Disorders
 Types of Bleeding Disorders
 Types of Bleeds
 Bleeding Disorders and Women
 Caring for the Newly Diagnosed Child
 Psychosocial Issues
-Complications, including Inhibitors
-Inhibitors
 For Consumers
-For Providers
 The Challenge of Inhibitors
 Why Some Patients Develop Inhibitors
 Measuring Inhibitors
 Prognosis for Inhibitor Patients
 Social and Emotional Concerns
 References
 Discussion Group
 Future Therapies
 What are Clotting Disorders?
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Medical and Scientific Advisory Council
 Financial and Insurance Issues
 HANDI, NHF's Information Resource Center
 Resources
 Web Links
 Glossary

 

 

 
The Challenge of Inhibitors
 
 

Healthcare professionals face major therapeutic challenges when hemophilic patients develop inhibitors or antibodies that develop following replacement therapy.

The incidence of hemophilia is estimated to be 1:10,000 live male births. While an X-linked disorder, as many as 1/3 of new cases may have been caused from a spontaneous mutation. Within this population, inhibitors develop in approximately 15% to 30% of patients with hemophilia A and in 2% to 5% of patients with hemophilia B. These antibodies are alloimmune. Development of inhibitors may also occur in previously normal (nonhemophilic individuals) and is called acquired hemophilia. These antibodies are autoimmune. The kinetics of inhibitors vary between alloimmune and autoimmune; Type 1 kinetics with rapid binding and removal of the replacement coagulation factor representing those most commonly seen in hemophilia or alloimmune antibodies, and Type 2 kinetics seen in autoimmune antibodies or acquired hemophilia. Alloimmune antibodies in hemophilia are most commonly IgG immunoglobulins, most commonly subtype 1 and 4.

 

This section of our Web site is sponsored by: